Key clinical point: First-line avelumab maintenance was not more efficacious than chemotherapy in patients with advanced gastric cancer.
Major finding: Avelumab maintenance did not prolong overall survival relative to continued chemotherapy in the entire trial population (10.4 months vs. 10.9 months) or in patients with at least 1% of tumor cells positive for PD-L1 (16.2 months vs. 17.7 months).
Study details: A phase 3 randomized, controlled trial of 805 patients with untreated advanced HER2-negative gastric or gastroesophageal junction cancer who were given induction chemotherapy (JAVELIN Gastric 100 trial).
Disclosures: The trial was sponsored by EMD Serono and Merck KGaA, which market avelumab in collaboration with Pfizer. Dr. Moehler disclosed relationships with these companies and many others. Dr. Catenacci disclosed relationships with Merck and other companies.
Moehler MH et al. 2020 GI Cancers Symposium, Abstract 278.